Form 8-K - Current report:
SEC Accession No. 0001193125-25-060794
Filing Date
2025-03-24
Accepted
2025-03-24 06:10:08
Documents
14
Period of Report
2025-03-21
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d932774d8k.htm   iXBRL 8-K 31740
2 EX-99.1 d932774dex991.htm EX-99.1 10694
  Complete submission text file 0001193125-25-060794.txt   171685

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA avir-20250321.xsd EX-101.SCH 2860
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE avir-20250321_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE avir-20250321_pre.xml EX-101.PRE 11268
16 EXTRACTED XBRL INSTANCE DOCUMENT d932774d8k_htm.xml XML 3639
Mailing Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110
Business Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110 857-204-8109
Atea Pharmaceuticals, Inc. (Filer) CIK: 0001593899 (see all company filings)

EIN.: 460574869 | State of Incorp.: MA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39661 | Film No.: 25762143
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)